Inside the Alopecia Pipeline: A closer look at Veradermics’ VDPHL01, the potential first and only extended-release oral minoxidil treatment for hair regrowth in women and men

Study Investigator Neal Bhatia, MD, Director of Clinical Dermatology at Therapeutics Clinical Research in San Diego, CA, discusses the preliminary data from the male cohort in an ongoing Phase 2 trial of Veradermics’ VDPHL01. The Company utilized a proprietary extended-release technology to develop VDPHL01, and this release profile is intended to enable fast, consistent, and intense hair growth, while avoiding concentration spikes above minoxidil’s identified cardiac activity threshold. Learn more about the study and Veradermics here.